Ist die Verordnung einer Therapie von 150 000 CHF vertretbar? [Is prescription of a therapy costing 150,000 CHF reasonable?]

Détails

ID Serval
serval:BIB_60F85D761ED2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Ist die Verordnung einer Therapie von 150 000 CHF vertretbar? [Is prescription of a therapy costing 150,000 CHF reasonable?]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Peters S., von Moos R., Thurlimann B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
21/10/2015
Peer-reviewed
Oui
Volume
11
Numéro
491
Pages
1967-1972
Langue
allemand
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
The costs of medicinal products have increased substantially in the last decade. Access to medical innovations for all patients is in acute danger. This situation requires a political commitment by the wider community of caregivers, healthcare providers and industry. New pricing models are inevitable to garantee access to medical innovation for all people in our society. Further, we must require companies to be more transparent when setting drug prices and require an attitude of consensus on prices between these industries - financially sound. Finally, our health insurance system must accept some state control to avoid patient selection, but also know the precise margin of manoeuvre over time in terms of cost expenditures assigned to oncology.

Mots-clé
Drug Costs, Health Services Accessibility/economics, Humans, Insurance, Health/economics, Patient Selection, Prescription Drugs/administration & dosage, Prescription Drugs/economics, Switzerland
Pubmed
Création de la notice
08/02/2018 18:44
Dernière modification de la notice
20/08/2019 15:18
Données d'usage